OpenBiome Overview
Pro stress-test →OpenBiome is a nonprofit stool bank that expands safe access to fecal transplants and catalyzes research on the human microbiome. Over a decade, it helped thousands of patients overcome Clostridioides difficile (C. diff) through safe access to investigational fecal microbiota transplantation (FMT) therapy. When regulatory changes forced it to stop delivering these treatments, it shifted focus to research and infrastructure advancement.
Strategic Profile
Pro stress-test →Since its founding in 2013, OpenBiome shipped more than 56,000 FMT preparations to a network of 1,250 healthcare facilities. The organization now operates as a research and knowledge platform rather than an active treatment provider, positioning itself within a competitive landscape that includes commercial players like Seres Therapeutics (FDA-approved pill form) and research-focused microbiome companies advancing defined bacterial therapeutics.
Competitive Landscape
Pro stress-test →OpenBiome operates in a consolidating microbiome therapeutics market dominated by venture-backed and public companies pursuing defined bacterial approaches. Key competitors include Seres Therapeutics (FDA-approved Vowst pill), Vedanta Biosciences (synthetic bacterial consortium), Finch Therapeutics (stool-derived treatments), and Rebiotix (now part of larger pharma), all moving away from whole-stool FMT toward manufactured alternatives.
Industry Context
OpenBiome operates in Microbiome therapeutics.
Key facts
Founded: 2013 · Headquarters: Cambridge, US · Employees: 70 · Revenue: N/A · Market cap: N/A